Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Musculoskeletal disease

Muscular dystrophy

Wingless-type MMTV integration site family member 7A (WNT7A)

Mouse studies suggest increasing WNT7A signaling could help treat muscular dystrophy. In the mdx mouse model of muscular dystrophy, plasmids that mediated Wnt7a expression increased muscle weight and muscle strength compared with control plasmids. Next steps include optimizing and producing the protein for therapeutic use.
Fate Therapeutics Inc.'s FT301, a WNT7A analog, is in preclinical development to treat muscular dystrophy.

SciBX 5(48); doi:10.1038/scibx.2012.1258
Published online Dec. 13, 2012

Covered by pending patents; licensed to Fate Therapeutics

Von Maltzahn, J. et al. Proc. Natl. Acad. Sci. USA; published online Nov. 26, 2012;
doi:10.1073/pnas.1215765109
Contact: Michael A. Rudnicki, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
e-mail:
mrudnicki@ohri.ca